Brought to you by 
Eisai gets cancer candidate rights from SymBio
Aug 2008
Executive Summary
Japanese drug start-up SymBio Pharmaceuticals has granted Eisai (neurology, cancer, and immune disorder therapeutics) co-development and exclusive commercialization rights in Japan to its bendamustine (SyB L0501) oncology candidate.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Eisai gets cancer candidate rights from SymBio
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice